Project

NEWTBVAC - Discovery and preclinical development of new generation tuberculosis vaccines

Het ontdekken, testen en doorontwikkelen van nieuwe, tweede generatie tubercolose-vaccins.

Meer informatie is te vinden op de speciale website van dit project.

Wageningen Bioveterinary Research

Contactformulier

Wageningen Bioveterinary Research

Contactformulier

Projectinformatie

NEWTBVAC - Discovery and preclinical development of new generation tuberculosis vaccines

Projectcode:: NEWTBVAC (241745)
Status:: Afgerond
Start project:: 1-jan-2010
Einde project:: 31-dec-2013

Partners:

Wageningen Bioveterinary Research

Overige betrokken organisaties:

Statens Serum Institut, Eberhard Karls Universitaet Tuebingen, Universitaet Ulm, Academisch Ziekenhuis Leiden- Leids Universitair medisch Centrum, Institut Scientifique de Sante Publique, GSK Biologicals, Centre National de la Recherche Scientifique, Universitaetsspital Basel, Instituto Superiore Di Sanita, Universite de GeneveThe Chancellor, Masters and Scholars of the University of Oxford, Friedrich-Alexander Universitaet Erlnagen-Nuernberg, Aston University, Institute Pasteur de Lille, Universite Libre de Bruxelles, Netherlands Vaccine Institute, Institut Pasteur, Institut Pasteur Korea, Universidad de Zaragoza, Max Planck Gesellschaft zur Foerderung Der Wissenschaften E.V., Universitaet Zuerich, Universita Degli Studi Di Padova, Health Protection Agency HPA, Stichting Biomedical Primate Center, Educational Foundation Yonsei University, International Vaccine Institute, Fundacio Institut De Investigado de Ciencies De La Salut Germans Trias I Pujol, National Biological Standards Board, London School of Hygiene and Tropical Medicine, Universita Degli Studi Di Palermo, University College London, Fondazione Per Lâ€™Istituto Di Ricerca in Biomedicina, PXâ€™Therapeutics